Sandoz Follows US Denosumab Filing With European Acceptance

Dual Filings With EMA For Prolia/Xgeva Biosimilars Confirmed By Novartis Unit

 
• By Dave Wallace

Sandoz has confirmed dual European filings for its denosumab biosimilar rival to Prolia and Xgeva, a few months after it submitted its candidate in the US.

Two jigsaw pieces with US and EU flags
Sandoz is following its US denosumab filing with an EU submission • Source: Shutterstock

More from Biosimilars

More from Products